CSF3 and neoplasm: Consistent with observations for Csf3 KD mammary cancer cells, pharmacological inhibition of G-CSFR alleviated vessel remodelling in macroscopic bone lesions and offered modest protection against tumour-induced bone degradation (Fig. 8e, f and Supplementary Fig. 6a–d).